6:03 PM
 | 
Jan 26, 2018
 |  BioCentury  |  Finance

All together now

Why long-time independent small caps BioCryst, Idera decided to merge

Promising proof-of-concept data from BioCryst Pharmaceuticals Inc. and a management team from Idera Pharmaceuticals Inc. with the requisite market know-how proved the right combination for a merger of two of the industry’s longest-standing independent small caps.

BioCryst was founded in 1986 and completed its IPO in 1994. Despite a series of setbacks, the company persisted to reach an all-time high valuation of $1.2 billion in July 2015, the peak of the biotech market. BioCryst closed on Friday with a market cap of $457.6 million.

Read the full 405 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >